What to Do If Wegovy Leaked Out of Your Injection Site: A Clinical Decision Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Small droplets (one to three drops) after injection represent 0.03 to 0.09 mL of lost medication, which is 3-9% of a typical dose and rarely requires intervention
• Wait 10 seconds after the dose counter reaches zero before withdrawing the needle to prevent backflow through the needle track
• Do not re-inject the same dose immediately, as you cannot accurately measure how much medication was lost and risk overdosing
• Document the leakage event, monitor for reduced efficacy over the next week, and contact your provider only if you see clear droplets larger than 0.2 mL or experience unusual side effects

Direct answer (40-60 words)

If Wegovy leaked after injection, do not re-inject. Small droplets (1-3 drops) represent minor loss that won't significantly affect your dose. Clean the site with gauze, apply light pressure for 30 seconds, and document the event. Contact your provider only if you saw substantial leakage (more than 5-6 drops) or experience unexpected symptoms.

Table of contents

1. Why medication leaks from injection sites
2. How much leakage actually matters (the volume calculation most articles get wrong)
3. The immediate response protocol
4. When to contact your provider versus when to wait
5. The re-dose question and why the answer is almost always no
6. What FormBlends clinical data shows about leakage patterns
7. The 10-second hold technique (and why 6 seconds isn't enough for pre-filled pens)
8. Injection-site selection and the leakage-risk hierarchy
9. Needle gauge, length, and their effect on backflow
10. Compounded semaglutide versus pre-filled pens: leakage comparison
11. The three failure modes of subcutaneous injection
12. FAQ

Why medication leaks from injection sites

Medication leakage after subcutaneous injection occurs through one of three mechanisms, each with different clinical significance:

Mechanism 1: Needle-track backflow. When you withdraw the needle immediately after injection, the medication follows the needle track back to the skin surface. The track is a 4-6 mm column of disrupted tissue that acts as a low-resistance path. This is the most common cause of visible leakage and accounts for roughly 70% of reported events (Frid et al., Mayo Clinic Proceedings, 2016).

Mechanism 2: Insufficient subcutaneous pocket depth. If the needle doesn't reach true subcutaneous tissue (the layer between skin and muscle), the medication deposits in the dermal layer, which has higher tissue pressure and less absorption capacity. The pressure differential forces medication back through the injection site. This happens most often with short needles (4 mm) used on patients with low body fat or when skin isn't properly pinched.

Mechanism 3: Injection-site saturation. Repeatedly injecting the same anatomical area creates localized lipohypertrophy (fatty tissue thickening) or scar tissue. These areas have reduced vascular flow and higher interstitial pressure, which resists medication absorption and increases surface leakage. A 2018 study found that patients who rotated injection sites had 64% less leakage than those who didn't (Gentile et al., Diabetes Therapy, 2018).

The Wegovy pen specifically delivers 0.25 to 2.4 mL per dose depending on your prescribed strength (0.25 mg = 0.17 mL, 2.4 mg = 1.6 mL at the 1.5 mg/mL concentration). The pen's spring-loaded plunger delivers medication at approximately 0.3 mL per second, which is faster than manual syringe injection and creates slightly higher tissue pressure during delivery.

How much leakage actually matters (the volume calculation most articles get wrong)

Most patient-education materials say "a drop or two doesn't matter" without quantifying what that means. Here's the actual math:

A standard drop of aqueous solution is 0.03 to 0.05 mL depending on surface tension and temperature. Wegovy solution at room temperature has slightly higher viscosity than water, so drops tend toward the larger end: approximately 0.04 mL per visible drop.

Leakage volume table:

The error in most published guidance is treating all "small leakage" the same. One drop from a 0.25 mg starter dose (0.17 mL total) represents 23% of the dose. One drop from a 2.4 mg maintenance dose (1.6 mL total) represents 2.5% of the dose. The clinical significance differs by an order of magnitude.

The threshold that matters: pharmacokinetic studies of semaglutide show that dose variations under 15% produce no measurable difference in steady-state blood levels after 4 weeks of weekly dosing (Kapitza et al., Clinical Pharmacokinetics, 2015). The half-life of semaglutide is 7 days, which means each weekly dose contributes to a cumulative steady state. A single 10% loss is compensated by the overlapping half-lives of previous doses.

Leakage becomes clinically significant when:

• You lose more than 0.2 mL (roughly 5 drops) from any single injection
• You experience leakage on consecutive weeks
• You're on a starter dose where 15% represents a larger absolute mg amount

The immediate response protocol

Step 1 (0-10 seconds post-injection): If you notice leakage while the needle is still in the skin, do not attempt to push the plunger again. The dose counter has already registered the full dose delivery. Additional pressure will not redirect lost medication into tissue.

Step 2 (immediately after withdrawal): Place a clean gauze pad or alcohol swab over the injection site. Apply light pressure for 30 seconds. Do not rub. Rubbing spreads medication across the skin surface and increases the risk of local irritation.

Step 3 (documentation): Note the following in your medication log or phone:

• Date and time of injection
• Injection site (abdomen left/right, thigh left/right, upper arm)
• Estimated leakage volume (number of visible drops)
• Whether you felt unusual resistance during injection
• Current dose strength

Step 4 (site care): Clean the injection site with soap and water if medication is visibly pooled on skin. Semaglutide solution has a pH of approximately 7.4 and is non-irritating to intact skin, but dried medication can cause mild itching in some patients.

Step 5 (observation window): Monitor the injection site for 2 hours. Normal responses include mild redness (less than 1 cm diameter), slight swelling, or tenderness. Contact your provider if you develop a raised welt larger than 2 cm, spreading redness, or pain that worsens after the first hour.

What not to do:

• Do not re-inject immediately
• Do not apply ice (cold constricts blood vessels and further reduces absorption)
• Do not apply heat (increases systemic absorption rate unpredictably)
• Do not take an extra dose later in the week to "make up" for the loss

When to contact your provider versus when to wait

Contact your provider within 24 hours if:

• You saw a visible stream of medication (not drops) leak from the site
• You estimate losing more than 0.2 mL (roughly 5-6 drops)
• You're on a starter dose (0.25 mg or 0.5 mg) and lost any visible amount
• The injection site develops a hard lump larger than 1 cm that doesn't resolve in 2 hours
• You experience unusual side effects within 48 hours (severe nausea beyond your typical response, vomiting more than twice, blood sugar below 70 mg/dL if you monitor glucose)

Wait and observe if:

• You saw 1-3 drops of clear liquid
• You're on a maintenance dose (1 mg or higher)
• The injection site looks normal or has only mild redness
• You have no new symptoms

The decision tree most patients actually need:

Did you see medication leak? ├─ No → Normal injection, no action needed └─ Yes → How much? ├─ Wet site, no visible drops → Document, no other action ├─ 1-3 drops → Document, monitor efficacy this week ├─ 4-6 drops → Document, contact provider for guidance └─ Stream or pooling → Contact provider same day